ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A americanpharmaceuticalreview
March 05, 2021The U.S. Food and Drug Administration (FDA) approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of ... -
FDA approves Nulibry to treat Molybdenum Cofactor Deficiency Type A pharmatimes
March 02, 2021The US Food and Drug Administration (FDA) has approved BridgeBio Pharma and Origin Biosciences’ Nulibry (fosdenopterin), making it the first treatment to be authorised to reduce the risk of mortality in patients with molybdenum cofactor deficiency ...
Pharma Sources Insight January 2025
